Riskpilot← Back to searchSign inGet full access2A Pharma AB
ABActiveOrg 5590902788Båtbyggaregatan 44Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
SEK 0
EBITDA margin
—
-4% vs 2023
Equity ratio
99.8%
Financial strength
Net profit 2024
SEK -793K
-4% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -801K | -4% |
| Net profit | SEK -793K | -4% |
| Total assets | SEK 3,2M | -32% |
| Equity | SEK 3,2M | -20% |
| Employees | 0 | — |
Legal name
2A Pharma AB
Org number
5590902788
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 december 2016
Share capital
SEK 143 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Bruun-Nyzell, Preben i förening med en av ledamöterna Firman tecknas av Lainevool, Peter Christian i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling och kommersialisering av läkemedel samt därmed förenlig verksamhet.
Address
Båtbyggaregatan 44
Email
pbn@2apharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | −13 563 | −17 786 | −11 431 | −13 183 | −10 181 | −8 744 | −772 | −801 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −13 563 | −17 786 | −11 431 | −13 183 | −10 181 | −8 744 | −772 | −801 |
| Net financials | −1 | −180 | −210 | — | −867 | −874 | 7 | 8 |
| Profit before tax | −13 564 | −17 876 | −11 536 | −13 183 | −11 049 | −9 617 | −765 | −793 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −13 564 | −17 876 | −11 536 | −13 183 | −11 049 | −9 617 | −765 | −793 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 11 939 | 12 579 | 7 934 | 5 913 | 11 461 | 926 | 4 659 | 3 167 |
| Equity | 11 014 | 11 987 | 6 072 | 4 283 | −6 765 | 717 | 3 952 | 3 160 |
| Long-term debt | 0 | 0 | 0 | 0 | 16 867 | 0 | 0 | 0 |
| Short-term debt | 925 | 592 | 1 862 | 1 630 | 1 359 | 209 | 707 | 7 |
| Total debt | 925 | 592 | 1 862 | 1 630 | 18 226 | 209 | 707 | 7 |
EBITDA margin
-80100000.0%
This company
15.8%
Market median
-506962125% vs market
20172024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20172024
Return on equity
-25.1%
This company
18.4%
Market median
-236% vs market
20172024
Net profit margin
-79300000.0%
This company
8.1%
Market median
-979012446% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-12-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Chief Auditor | Chief Auditor | 2020 | — | — |
PB Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of 2A Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Preben Bruun-Nyzell | Chief Executive Officer | 0 companies |
| Peter Christian Lainevool | Chairman | 0 companies |
| Søren Nielsen | Board of Directors | 0 companies |
| Jens Renstrup | Board of Directors | 0 companies |
| Josephus Dirk Nieland | Board of Directors | 0 companies |